Mometasone furoate nasal spray is used for the prophylaxis and treatment of nasal symptoms of seasonal allergic rhinitis and for the treatment of nasal symptoms of perennial allergic rhinitis.
In patients with seasonal or perennial allergic rhinitis, intranasal administration of mometasone furoate is more effective than placebo and appears to be as effective as other intranasal corticosteroids (e.g., beclomethasone dipropionate, fluticasone propionate) in relieving moderate to severe nasal symptoms, including stuffiness, rhinorrhea, itching, and sneezing. In patients with seasonal or perennial rhinitis, maximum benefit usually occurs within 1-2 weeks of continuous intranasal mometasone furoate therapy, although symptomatic relief may be evident within as little as 5-11 hours after the initial dose.
Prophylactic administration of mometasone furoate nasal spray beginning 2-4 weeks prior to the onset of the pollen season in patients with seasonal allergic rhinitis resulted in a smaller increase in nasal symptoms than with placebo.
Mometasone furoate nasal spray is used in the management of nasal polyposis. In 2 placebo-controlled trials evaluating intranasal mometasone furoate therapy (200 mcg once or twice daily for 4 months) in patients with existing bilateral nasal polyps, reductions in the size of polyps and the degree of nasal congestion were observed with mometasone furoate at a dosage of 200 mcg twice daily. At a dosage of 200 mcg once daily, an effect of mometasone furoate on reduction in the size of nasal polyps was not consistently demonstrated.